US Patent

US8460641 — Microemulsion process and composition

Method of Use · Assigned to Stiefel Research Australia Pty Ltd · Expires 2027-08-13 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a microemulsion process and composition for dermal delivery of at least one pharmaceutically active ingredient.

USPTO Abstract

An oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1412 — Verdeso
U-1410 — Temovate

Patent Metadata

Patent number
US8460641
Jurisdiction
US
Classification
Method of Use
Expires
2027-08-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Stiefel Research Australia Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.